<DOC>
	<DOCNO>NCT00002604</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness O ( 6 ) -benzylguanine carmustine treat patient solid tumor .</brief_summary>
	<brief_title>O ( 6 ) -Benzylguanine Carmustine Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine biochemical modulation dose l O6-benzylguanine ( BG ) , define dose baseline O6-alkylguanine DNA alkyltransferase ( AGT ) activity circulate peripheral blood mononuclear cell ( PBMC ) decrease great 90 % patient advance solid tumor 2 hour BG infusion . II . Determine biochemical modulation dose t/18 ( BMDt/18 ) BG , define dose AGT activity human metastatic tumor tissue decrease undetectable level 18 hour BG infusion . III . Determine maximum tolerate dose carmustine ( BCNU ) administer BG BMDt/18 patient . IV . Determine toxicities BG BCNU patient . V. Determine pharmacokinetic parameter BG administer BMDt/18 , determine effect BCNU BG pharmacokinetics . VI . Assess antitumor response patient metastatic solid tumor treat regimen . VII . Determine effect lower , frequent bolus dos continuous infusion BG depletion AGT activity PBMC tumor tissue patient . VIII . Determine pharmacokinetics BG low , frequent bolus dos continuous infusion . OUTLINE : This dose escalation study 06-benzylguanine ( BG ) carmustine ( BCNU ) . Patients receive BG IV 1 hour week 1 , BG IV 1 hour follow 1 hour later BCNU IV 1 hour week 3 . Courses repeat every 6 week absence disease progression unacceptable toxicity . Cohorts 1-3 patient receive escalate dos BG biochemical modulation dose l ( BMDl ) determine . The BMDl define dose baseline O6-alkylguanine DNA alkyltransferase ( AGT ) activity circulate peripheral blood mononuclear cell decrease great 90 % 2 hour BG infusion . Cohorts 3 patient receive escalate dos BG begin BMDl biochemical modulation dose t/2 ( BMDt/2 ) determine . The BMDt/2 define dose AGT activity human metastatic tumor tissue decrease great 90 % 2 hour BG infusion . Cohorts 3 patient receive escalate dos BG begin BMDt/2 biochemical modulation dose t/18 ( BMDt/18 ) determine . The BMDt/18 define dose AGT activity human metastatic tumor tissue decrease undetectable level 18 hour BG infusion . Patients receive BG IV 1 hour follow 1 hour later BCNU IV 1 hour week 1 . Courses repeat every 6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos BCNU combine BG BMDt/18 maximum tolerate dose ( MTD ) BCNU determine . The MTD BCNU define dose precede 2 6 patient experience dose limit toxicity . A cohort 3 patient receive BG IV 2 minute another cohort 3 patient receive BG IV 24 hour . An additional cohort 6 patient receive BG IV 24 hour BCNU IV 1 hour begin 2 hour BG infusion week 3 . PROJECTED ACCRUAL : A total 51 patient accrue study 36 month .</detailed_description>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor standard treatment exists ( include surgery , radiotherapy , systemic agent ) No primary CNS malignancy No CNS metastases Only disease sequentially biopsied eligible determination biochemical modulating dose decrease AGT tumor tissue PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Hematopoietic : WBC great 4,000/mm3 Absolute neutrophil count great 2,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL AST le 3 time normal Prothrombin time less upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Calcium normal Electrolytes normal Other : Diabetes control diet insulin allow Not pregnant Fertile patient must use effective contraception 2 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since chemotherapy ( 6 week since mitomycin ) recover No prior nitrosoureas Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>